Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
PLoS One
2014 Jan 01;96:e100209. doi: 10.1371/journal.pone.0100209.
Show Gene links
Show Anatomy links
From pan-reactive KV7 channel opener to subtype selective opener/inhibitor by addition of a methyl group.
Blom SM
,
Rottländer M
,
Kehler J
,
Bundgaard C
,
Schmitt N
,
Jensen HS
.
???displayArticle.abstract???
The voltage-gated potassium channels of the KV7 family (KV7.1-5) play important roles in controlling neuronal excitability and are therefore attractive targets for treatment of CNS disorders linked to hyperexcitability. One of the main challenges in developing KV7 channel active drugs has been to identify compounds capable of discriminating between the neuronally expressed subtypes (KV7.2-5), aiding the identification of the subunit composition of KV7 currents in various tissues, and possessing better therapeutic potential for particular indications. By taking advantage of the structure-activity relationship of acrylamide KV7 channel openers and the effects of these compounds on mutant KV7 channels, we have designed and synthesized a novel KV7 channel modulator with a unique profile. The compound, named SMB-1, is an inhibitor of KV7.2 and an activator of KV7.4. SMB-1 inhibits KV7.2 by reducing the current amplitude and increasing the time constant for the slow component of the activation kinetics. The activation of KV7.4 is seen as an increase in the current amplitude and a slowing of the deactivation kinetics. Experiments studying mutant channels with a compromised binding site for the KV7.2-5 opener retigabine indicate that SMB-1 binds within the same pocket as retigabine for both inhibition of KV7.2 and activation of KV7.4. SMB-1 may serve as a valuable tool for KV7 channel research and may be used as a template for further design of better subtype selective KV7 channel modulators. A compound with this profile could hold novel therapeutic potential such as the treatment of both positive and cognitive symptoms in schizophrenia.
???displayArticle.pubmedLink???
24956197
???displayArticle.link???PLoS One
Aiken,
Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer.
1995, Pubmed
Aiken,
Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer.
1995,
Pubmed
Bentzen,
The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels.
2006,
Pubmed
,
Xenbase
Biervert,
A potassium channel mutation in neonatal human epilepsy.
1998,
Pubmed
,
Xenbase
Blackburn-Munro,
The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain.
2003,
Pubmed
Blom,
The acrylamide (S)-2 as a positive and negative modulator of Kv7 channels expressed in Xenopus laevis oocytes.
2009,
Pubmed
,
Xenbase
Blom,
Differential effects of ICA-27243 on cloned K(V)7 channels.
2010,
Pubmed
,
Xenbase
Brown,
Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone.
1980,
Pubmed
Chadha,
Contribution of kv7.4/kv7.5 heteromers to intrinsic and calcitonin gene-related peptide-induced cerebral reactivity.
2014,
Pubmed
Chadha,
Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies impaired β-adrenoceptor-mediated relaxation of renal arteries in hypertension.
2012,
Pubmed
Charlier,
A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family.
1998,
Pubmed
Duncan,
An integrated view of pathophysiological models of schizophrenia.
1999,
Pubmed
Greenwood,
New tricks for old dogs: KCNQ expression and role in smooth muscle.
2009,
Pubmed
Gribkoff,
The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update.
2008,
Pubmed
Hansen,
The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
2006,
Pubmed
Hansen,
The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.
2007,
Pubmed
Hansen,
Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS.
2008,
Pubmed
Jentsch,
Neuronal KCNQ potassium channels: physiology and role in disease.
2000,
Pubmed
Khanamiri,
Contribution of Kv7 channels to basal coronary flow and active response to ischemia.
2013,
Pubmed
Korsgaard,
Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels.
2005,
Pubmed
,
Xenbase
Lange,
Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels.
2009,
Pubmed
,
Xenbase
Lieberman,
Provocative tests with psychostimulant drugs in schizophrenia.
1987,
Pubmed
Mackie,
Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention.
2008,
Pubmed
Miceli,
Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs.
2008,
Pubmed
Mueser,
Schizophrenia.
2004,
Pubmed
Padilla,
The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
2009,
Pubmed
Redrobe,
Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.
2012,
Pubmed
,
Xenbase
Risgaard,
Radiolabelling and PET brain imaging of the α₁-adrenoceptor antagonist Lu AE43936.
2013,
Pubmed
Schenzer,
Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
2005,
Pubmed
,
Xenbase
Seeman,
Dopamine receptors and the dopamine hypothesis of schizophrenia.
1987,
Pubmed
Singh,
A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns.
1998,
Pubmed
Sotty,
Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission.
2009,
Pubmed
Stott,
K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders.
2014,
Pubmed
Søgaard,
KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology.
2001,
Pubmed
,
Xenbase
Talebizadeh,
Novel mutation in the KCNQ4 gene in a large kindred with dominant progressive hearing loss.
1999,
Pubmed
Wang,
KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.
1998,
Pubmed
,
Xenbase
Wu,
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.
2003,
Pubmed
,
Xenbase
Wu,
Synthesis and structure-activity relationship of acrylamides as KCNQ2 potassium channel openers.
2004,
Pubmed
,
Xenbase
Wu,
(S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons.
2004,
Pubmed
Wuttke,
The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
2005,
Pubmed
,
Xenbase
Xiong,
Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers.
2008,
Pubmed
